We claim:

1. A recombinant modified Vaccinia Ankara (MVA) for use in the treatment of cancer comprising: a) a first nucleic acid encoding a tumor-associated antigen (TAA); and b) a second nucleic acid encoding 4-1BBL; wherein the recombinant MVA is to be administered to a subject intratumorally.

2. The recombinant MVA for use of claim 1, wherein the intratumoral administration of the recombinant MVA enhances an inflammatory response in a cancerous tumor, reduces the size of the cancerous tumor, and/or increases overall survival of ~~the~~a human patient as compared to a non-intratumoral injection of said recombinant MVA.

~~2.~~ 3. The recombinant MVA for use of claim 1 or 2, further comprising c) a third nucleic acid encoding CD40L.

~~3.~~ 4. The recombinant MVA for use of ~~claim~~any one of claims 1 to 3, wherein the TAA is an endogenous retroviral (ERV) protein.

~~4.~~ 5. The recombinant MVA for use of claim ~~3~~4, wherein the ERV protein is from the human endogenous retroviral K (HERV-K) family and is selected from HERV-K-env and HERV-K-gag.

~~5.~~ 6. The recombinant MVA for use of ~~claim~~any one of claims 1 to 3, wherein the TAA is selected from the group consisting of carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER-2), survivin, tyrosine related protein 1 (TRP1), tyrosine related protein 1 (TRP2), Brachyury, FOLR1, PRAME, HERV-K-env, HERV-K-gag, p15, MEL, and combinations thereof.

~~6.~~ 7. The recombinant MVA for use of ~~claim~~any one of claims 1 ~~further comprising c) a third nucleic acid encoding CD40L.~~

~~7. A pharmaceutical combination comprising: (a)~~to 6, wherein the recombinant MVA ~~of claim 1 or claim 6; and (b) at least one~~is to be administered to the subject in combination with either an immune checkpoint molecule antagonist or agonist.

8. The ~~pharmaceutical combination~~recombinant MVA for use of claim 7, wherein the immune checkpoint molecule antagonist or agonist is selected from an antagonist or agonist of CTLA-4, PD-1, PD-L1, LAG-3, TIM-3, and ICOS.

9. The recombinant MVA for use of any one of claims 1 to 6, wherein the recombinant MVA is to be administered to a subject in combination with an antibody specific for a TAA.